Abstract:Objective To explore the clinical effect of Clopidogrel combined with Urokinase thrombolysis in the treatment of patients with ST-elevation myocardial infarction. Methods Fifty patients with ST-segment elevation myocardial infarction treated in our hospital from August 2015 to August 2019 were selected as subjects.By a random number table method, they were divided into the control group (n=25) and the observation group (n=25).Patients in the control group were treated with thrombolytic therapy with Urokinase thrombolysis.Patients in the observation group were treated with Clopidogrel combined with Urokinase thrombolytic therapy.The levels of inflammatory factors, myocardial function indicators, myocardial injury and cardiovascular events were compared between the two groups. Results After treatment, the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and left ventricular end-diastolic dimension(LVEDD) decreased and the level of left ventricular ejection fraction (LVEF) increased, the levels of serum IL-6, TNFα, and LVEDD in the observation group were lower than those of the control group, while LVEF level was higher than that of the control group, and the differences were statistically significant (P<0.05).After treatment, the levels of cardiac troponin-T (cTnT), creatine kinase-MB (CK-MB), and brain natriuretic peptide (BNP) of patients in the two groups decreased, the levels of cTnT, CK-MB, and BNP in the observation group were lower than those in the control group, with statistically significant differences (P<0.05).The total incidence of cardiovascular disease in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion The application of Clopidogrel combined with Urokinase thrombolysis in patients with ST-segment elevation myocardial infarction can effectively reduce patients′ inflammatory factors and myocardial damage, improve myocardial function, and effectively decrease the incidence of recurrent cardiovascular disease.The therapeutic effect is safe and effective, and it is worth popularizing and applying.
徐国旺. 氯吡格雷联合尿激酶溶栓治疗ST段抬高心肌梗死患者的临床效果[J]. 中国当代医药, 2020, 27(15): 59-62.
XU Guo-wang. Clinical effect of Clopidogrel combined with Urokinase thrombolysis in the treatment of patients with ST-elevation myocardial infarction. 中国当代医药, 2020, 27(15): 59-62.